Bibliography
- TALLEY JJ, BERTENSHAW SR, BROWN DL et al.: N-[[(5-methyl-3-phenylisoxazol-4-y1)-phenyl] sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. J. Med. Chem. (2000) 43:1661–1663.
- ••The only publication describing the chemistry and pharma-cology of parecoxib by the scientists of the manufacturing company.
- FOSSLIEN E: Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann. Clin. Lab. Sci. (1998) 28 (2) :67–81.
- JAIN KK: Pain therapeutics: re-evaluation of strategies. Reuters Business Insight, London (2000):August.
- ••A detailed description of pain mechanisms, analgesics indevelopment and critical evaluation of strategies for management of pain.
- CLEMETT D, GOA KL: Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs (2000) 59:957–980.
- TIPPS LB, COPLIN WM, MURRY KR et al: Safety and feasibility of continuous infusion of remifentanil in the neurosurgical intensive care. Neurosurgery (2000) 46:596–602.
- AIDA S, YAMAKURA T, BABA H et al: Pre-emptiveanalgesia by iv. low-dose ketamine and epidural morphine in gastrectomy: a randomized double-blind study. Anesthesiology (2000) 92:1624–1630.
- JAIN KK: An evaluation of intrathecal zicono tide for the treatment of chronic pain. Exp. Opin. Invest. Drugs (2000) 9(10:2403–2410.
- HARGREAVES K, DUBNER R, BROWN F et al.: Anew and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain (1988) 32:77–88.
- TALLEY JJ, BROWN DL, CARTER JS et al: 445-methy1-3- phenylisoxazo1-4zen esulfon amide,valdecoxib: A potent and selective inhibitor of COX-2. J. Med. Chem. (2000) 43:775–777.
- MEHLISCH D, KUSS M, BAUMAN A et al: Correlation ofpharmacokinetics (PK) with onset and duration of analgesia of im. doses of parecoxib in postoperative dental pain. Clin. Pharmacol. Ther. (2000) 67(2) :PIII–7.
- INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN (PARTIddb Meeting Report. Vienna, Austria (23-27August 1999).
- DANIELS SE, KUSS M, MEHLISCH DR et al.: Pharmacoki-netic and efficacy evaluation of iv. parecoxib in a postsurgical dental pain model. Clin. Pharmacol Ther. (2000) 67 (2):PL1–8. Abstract.
- HUBBARD RC, KUSS ME, LECOMTE DL et al.: An endoscopic study of the gastroduodenal effects of SC-69142A, a parenteral COX-2-specific inhibitor in the elderly. Gastroenterology (2000) 118 (Suppl. 2):Abstract 1455.
- JAIN KK: A guide to drug evaluation for chronic pain. Emerging Drugs (2000) 5:241–257.
- NIEMI TT, BACKMAN JT, SYRJALA MT et al.: Platelet dysfunction after iv. ketorolac or propacetamol. Acta Anaesthesiol. Scand. (2000) 44:69–74.
- GOODMAN SB: Use of COX-2 specific inhibitors in operative and nonoperative management of patients with arthritis. Orthopedics (2000) 23 (Suppl. 7):S765–768.
- MUSCARA MN, MCKNIGHT W, ASFAHA S et al: Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor. Br. J. Pharmacol. (2000) 129:68–66.
- NOBLE SL, KING DS, OLUTADE JI: Cyclooxygenase-2enzyme inhibitors: place in therapy. Am. Fam. Physician (2000) 61:3669–3676.
- JACKSON LM, HAWKEY CJ: COX-2 selective nonster-oidal anti-inflammatory drugs: do they really offer any advantages? Drugs (2000) 59:1207-1216. Kewel K Jain